Interview with the President, CEO and Chairman: Ocular Therapeutix Inc. (NASDAQ:OCUL)

Healthcare >> CEO Interviews >> April 22, 2016

Amarpreet Sawhney, Ph.D., has served as Ocular Therapeutix, Inc.’s President and Chief Executive Officer and a board member since co-founding the company in 2006, and he was elected as Chairman of the board in June 2014. Dr. Sawhney served as CEO of Augmenix, an affiliate of Ocular Therapeutix, from 2008 until April 2014, and currently serves as Chairman of the board. In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical, and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of AccessClosure, Inc., acquired by Cardinal Health in 2014. Dr. Sawhney’s innovations are the subject of over 100 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a Bachelor of Technology in chemical engineering from the Indian Institute of Technology, Delhi, India. Profile

TWST: Please start by introducing our readers to the company with some background information on its founding and history and its focus today.

Dr. Sawhney: Ocular

Join for free to read a longer excerpt or purchase this article

Interview with the President, CEO and Chairman: Ocular Therapeutix Inc. (NASDAQ:OCUL)

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Interview with the President, CEO and Chairman: Ocular Therapeutix Inc. (NASDAQ:OCUL)

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS